These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18763362)

  • 41. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.
    Christian JB; Lapane KL; Hume AL; Eaton CB; Weinstock MA;
    J Natl Cancer Inst; 2008 Sep; 100(17):1223-32. PubMed ID: 18728281
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy.
    Giles TD
    Rev Cardiovasc Med; 2007; 8 Suppl 2():S14-21. PubMed ID: 17401312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are there effects of renin-angiotensin system antagonists beyond blood pressure control?
    Bakris G
    Am J Cardiol; 2010 Jan; 105(1 Suppl):21A-9A. PubMed ID: 20102970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The importance of managing cardiovascular risk in the treatment of hypertension: the role of ACE inhibitors and ARBs.
    Pierson CA; Epstein BJ; Roberts ME
    J Am Acad Nurse Pract; 2008 Nov; 20(11):529-38. PubMed ID: 19128336
    [No Abstract]   [Full Text] [Related]  

  • 46. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent clinical trials: the good, the bad, and the misleading.
    Kaplan NM
    Hypertension; 2008 Oct; 52(4):608-9. PubMed ID: 18695142
    [No Abstract]   [Full Text] [Related]  

  • 48. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 49. What evidence supports guidelines for use of ACE inhibitors and ARBs in diabetes?
    Curtiss FR
    J Manag Care Pharm; 2006 Oct; 12(8):690-1. PubMed ID: 17269849
    [No Abstract]   [Full Text] [Related]  

  • 50. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs.
    Vegter S; Nguyen NH; Visser ST; de Jong-van den Berg LT; Postma MJ; Boersma C
    Am J Manag Care; 2011 Sep; 17(9):609-16. PubMed ID: 21902446
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review.
    Ferrari R; Boersma E
    Expert Rev Cardiovasc Ther; 2013 Jun; 11(6):705-17. PubMed ID: 23750680
    [TBL] [Abstract][Full Text] [Related]  

  • 52. How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?
    Gustafsson F; Segura J; Ruilope LM
    J Hypertens; 2010 Aug; 28(8):1595-8. PubMed ID: 20613629
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Higher small arterial elasticity in hypertensive patients treated with angiotensin II receptor blockers.
    Takeuchi K; Ideishi M; Tashiro T; Morishige N; Yamada T; Saku K; Urata H
    Hypertens Res; 2005 Aug; 28(8):639-44. PubMed ID: 16392767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ACE inhibitors vs. ARBs for patients with diabetic kidney disease.
    Bailey J
    Am Fam Physician; 2007 Jul; 76(1):68-9. PubMed ID: 17668841
    [No Abstract]   [Full Text] [Related]  

  • 55. Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.
    Butt DA; Mamdani M; Gomes T; Lix L; Lu H; Tu K;
    J Bone Miner Res; 2014 Nov; 29(11):2483-8. PubMed ID: 24806397
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ACE inhibitors versus AT1 blockers in the treatment of hypertension and syndrome X.
    Feldman R
    Can J Cardiol; 2000 Aug; 16 Suppl E():41E-44E. PubMed ID: 10906626
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Angiotensin inhibitor or blocker? For controlling blood pressure, an ACE inhibitor is a good place to start.
    Harv Heart Lett; 2008 Feb; 18(6):2. PubMed ID: 27023946
    [No Abstract]   [Full Text] [Related]  

  • 58. The beneficial effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors on atrial electrical remodeling in patients with essential hypertension.
    Celik T; Iyisoy A; Kardesoglu E; Isik E
    Int J Cardiol; 2009 Feb; 132(2):265-7. PubMed ID: 18031850
    [No Abstract]   [Full Text] [Related]  

  • 59. [ACE inhibitors or ARBs for first-line treatment of arterial hypertension--who goes for the victory?].
    Trenkwalder P
    MMW Fortschr Med; 2014 Nov; 156(20):52-4. PubMed ID: 25543372
    [No Abstract]   [Full Text] [Related]  

  • 60. Change in blood pressure predicts regression of cardiac hypertrophy in patients of African ancestry receiving agents influencing the renin-angiotensin system.
    Libhaber EN; Norton GR; Libhaber CD; Candy GP; Woodiwiss AJ; Sliwa K; Essop MR; Sareli P
    J Hum Hypertens; 2005 Aug; 19(8):659-61. PubMed ID: 15905887
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.